Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies

E. P. Alessandrino, P. Bernasconi, A. A. Colombo, D. Caldera, L. Malcovati, D. Troletti, L. Vanelli, M. Verettoni, F. Montanari, M. Lazzarino

Research output: Contribution to journalArticle


The aim of this study was to investigate thiotepa (TT) and fludarabine (Fluda) as a preparative regimen for allogeneic peripheral stem cell transplant in patients not eligible for a standard myeloablative regimen due to comorbidities and/or poor performance status. TT was given at a dose of 10 mg/kg over 2 days and Fluda at 125 mg/m2 over 5 days. In all, 21 patients (14 male, seven female; 10 acute leukaemia, eight myelodysplastic syndrome, two non-Hodgkin's lymphoma, one Hodgkin's disease) were treated. The median age was 51 years (range 30-55 years). All patients achieved full donor-type chimaerism. Adverse events included mild nausea and vomiting in two patients and a slight increase of serum amylase in three. A total of 13 patients received RBC transfusions (median 6U, range 1-23), and all received platelets (median 4U, range 1-27). Four patients died of nonrelapse causes and five of relapse. The 1-year probabilities of transplant-related mortality and relapse were 19 and 29%, respectively. In total, 12 patients remain in complete remission (median follow-up: 786 days). The 3-year overall survival probability was 58%. We conclude that this regimen is feasible and well tolerated.

Original languageEnglish
Pages (from-to)1039-1045
Number of pages7
JournalBone Marrow Transplantation
Issue number12
Publication statusPublished - Dec 2004



  • Allogeneic stem cell transplantation
  • Fludarabine
  • Reduced-intensity conditioning regimen
  • Thiotepa

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this